Driving Clinical Trial Innovation.

Discusses the potential of the U.S. Food and Drug Administration's Critical Path Initiative to drive clinical trial innovation in the United States. Slowdown in the rate of promising medications and treatments actually reaching patients; Initiative's encouragement of cooperation between government, research institutions, and the pharmaceutical industry to solve procedural bottleneck problems and accelerate time to market; Advances in underlying clinical trial technologies.